#United States #Austin #Biomaterials #DiFusion Technologies #ZFUZE

DiFusion Technologies Secures Patent for ZFUZE®

Introduction
In a significant advancement for the field of surgical implants, DiFusion Technologies, based in Austin, Texas, recently announced the issuance of US Patent 12,178,936 B2. This patent focuses on the innovative methods for manufacturing ZFUZE®, a proprietary biomaterial that promises to revolutionize orthopedic surgery.

About ZFUZE®
ZFUZE® is a cutting-edge therapeutic material that boasts multiple properties: it is anti-inflammatory, osseoconductive, and capable of bearing substantial loads. As the first biomaterial of its kind to receive FDA clearance for spinal implants, ZFUZE® has demonstrated remarkable results in enhancing cellular and immunologic responses following surgical procedures.

A recent retrospective study involving 75 patients revealed an astonishing 93.4% fusion rate in patients who received lumbar spinal procedures using ZFUZE® within six months, substantially outperforming traditional materials, which showed an average fusion rate of only 68% after a year.

The Significance of the New Patent
Founder and CEO of DiFusion, Derrick Johns, emphasized the importance of this new patent, stating, "This new patent firmly protects our ZFUZE FDA Master File for another 17 years. ZFUZE is the only FDA cleared immuno-modulating biomaterial currently available to patients' surgeons and hospitals." The FDA Master File is crucial for protecting innovative technologies, as it allows the company to maintain exclusivity in this emerging market.

Johns further remarked on the extensive resources required to build such a file, a process often beyond the capacity of larger orthopedic firms which may not possess the scientific acumen to navigate its complexities.

DiFusion Technologies' Mission
DiFusion Technologies, Inc. stands at the forefront of advanced biomaterial innovations aimed at surgical implants. The company develops unique solutions that minimize the foreign body response typically triggered by implants, thereby accelerating healing times and reducing postoperative complications. Through a proprietary manufacturing process, DiFusion's implants significantly lower the chronic inflammation associated with conventional materials, ultimately leading to improved patient outcomes.

Conclusion
With the introduction of the ZFUZE® technology and the protective patent, DiFusion Technologies is poised to maintain its leadership in the development of advanced surgical materials. The medical community eagerly anticipates the positive impact of ZFUZE® on surgical practices and patient recovery moving forward.

For more information about DiFusion Technologies and its groundbreaking work, visit www.difusiontech.com.